001     127820
005     20240228140951.0
024 7 _ |a 10.1002/ijc.29205
|2 doi
024 7 _ |a pmid:25213452
|2 pmid
024 7 _ |a 0020-7136
|2 ISSN
024 7 _ |a 1097-0215
|2 ISSN
024 7 _ |a altmetric:17959990
|2 altmetric
037 _ _ |a DKFZ-2017-03842
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Yang, Rongxi
|0 P:(DE-He78)dd35af1fb84ec0812fe4bdea97d2f291
|b 0
|e First author
|u dkfz
245 _ _ |a DNA methylation array analyses identified breast cancer-associated HYAL2 methylation in peripheral blood.
260 _ _ |a Bognor Regis
|c 2015
|b Wiley-Liss
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1521793884_5360
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Breast cancer (BC) is the leading cause of cancer-related mortality in women worldwide. Changes in DNA methylation in peripheral blood could be associated with malignancy at early stage. However, the BC-associated DNA methylation signatures in peripheral blood were largely unknown. Here, we performed a genome-wide methylation screening and identified a BC-associated differentially methylated CpG site cg27091787 in the hyaluronoglucosaminidase 2 gene (HYAL2) (discovery round with 72 BC case and 24 controls: p = 2.61 × 10(-9) adjusted for cell-type proportions). The substantially decreased methylation of cg27091787 in BC cases was confirmed in two validation rounds (first validation round with 338 BC case and 507 controls: p < 0.0001; second validation round with 189 BC case and 189 controls: p < 0.0001). In addition to cg27091787, the decreased methylation of a 650-bp CpG island shore of HYAL2 was also associated with increased risk of BC. Moreover, the expression and methylation of HYAL2 were inversely correlated with a p-value of 0.006. To note, the BC-associated decreased HYAL2 methylation was replicated in the T-cell fraction (p = 0.034). The cg27091787 methylation level enabled a powerful discrimination of early-stage BC cases (stages 0 and I) from healthy controls [area under curve (AUC) = 0.89], and was robust for the detection of BC in younger women as well (age < 50, AUC = 0.87). Our study reveals a strong association between decreased HYAL2 methylation in peripheral blood and BC, and provides a promising blood-based marker for the detection of early BC.
536 _ _ |a 313 - Cancer risk factors and prevention (POF3-313)
|0 G:(DE-HGF)POF3-313
|c POF3-313
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
650 _ 7 |a Biomarkers, Tumor
|2 NLM Chemicals
650 _ 7 |a Cell Adhesion Molecules
|2 NLM Chemicals
650 _ 7 |a GPI-Linked Proteins
|2 NLM Chemicals
650 _ 7 |a Hyal2 protein, human
|0 EC 3.2.1.25
|2 NLM Chemicals
650 _ 7 |a Hyaluronoglucosaminidase
|0 EC 3.2.1.35
|2 NLM Chemicals
700 1 _ |a Pfütze, Katrin
|0 P:(DE-He78)83906db1355a576371363a4b9f107d3d
|b 1
|u dkfz
700 1 _ |a Zucknick, Manuela
|0 P:(DE-HGF)0
|b 2
700 1 _ |a Sutter, Christian
|b 3
700 1 _ |a Wappenschmidt, Barbara
|b 4
700 1 _ |a Marme, Frederik
|b 5
700 1 _ |a Qu, Bin
|b 6
700 1 _ |a Cuk, Katarina
|0 P:(DE-He78)0a8ada1f5d2ea05fc3af10cd808bfa9a
|b 7
|u dkfz
700 1 _ |a Engel, Christoph
|b 8
700 1 _ |a Schott, Sarah
|b 9
700 1 _ |a Schneeweiss, Andreas
|b 10
700 1 _ |a Brenner, Hermann
|0 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2
|b 11
|u dkfz
700 1 _ |a Claus, Rainer
|0 P:(DE-HGF)0
|b 12
700 1 _ |a Plass, Christoph
|0 P:(DE-He78)4301875630bc997edf491c694ae1f8a9
|b 13
|u dkfz
700 1 _ |a Bugert, Peter
|b 14
700 1 _ |a Hoth, Markus
|b 15
700 1 _ |a Sohn, Christof
|b 16
700 1 _ |a Schmutzler, Rita
|b 17
700 1 _ |a Bartram, Claus R
|b 18
700 1 _ |a Burwinkel, Barbara
|0 P:(DE-He78)15b7fd2bc02d5ef47a2fe2dd0140d2bf
|b 19
|e Last author
|u dkfz
773 _ _ |a 10.1002/ijc.29205
|g Vol. 136, no. 8, p. 1845 - 1855
|0 PERI:(DE-600)1474822-8
|n 8
|p 1845 - 1855
|t International journal of cancer
|v 136
|y 2015
|x 0020-7136
909 C O |o oai:inrepo02.dkfz.de:127820
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)dd35af1fb84ec0812fe4bdea97d2f291
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)83906db1355a576371363a4b9f107d3d
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 P:(DE-He78)0a8ada1f5d2ea05fc3af10cd808bfa9a
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 11
|6 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 12
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 13
|6 P:(DE-He78)4301875630bc997edf491c694ae1f8a9
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 19
|6 P:(DE-He78)15b7fd2bc02d5ef47a2fe2dd0140d2bf
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-313
|2 G:(DE-HGF)POF3-300
|v Cancer risk factors and prevention
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2015
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b INT J CANCER : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b INT J CANCER : 2015
920 1 _ |0 I:(DE-He78)C080-20160331
|k C080
|l Molekulare Epidemiologie
|x 0
920 1 _ |0 I:(DE-He78)C070-20160331
|k C070
|l Klinische Epidemiologie und Alternsforschung
|x 1
920 1 _ |0 I:(DE-He78)G110-20160331
|k G110
|l Präventive Onkologie
|x 2
920 1 _ |0 I:(DE-He78)C060-20160331
|k C060
|l Biostatistik
|x 3
920 1 _ |0 I:(DE-He78)C010-20160331
|k C010
|l Epigenomik und Krebsrisikofaktoren
|x 4
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C080-20160331
980 _ _ |a I:(DE-He78)C070-20160331
980 _ _ |a I:(DE-He78)G110-20160331
980 _ _ |a I:(DE-He78)C060-20160331
980 _ _ |a I:(DE-He78)C010-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21